[go: up one dir, main page]

WO2008049070A3 - Il-17c antagonists and methods of using the same - Google Patents

Il-17c antagonists and methods of using the same Download PDF

Info

Publication number
WO2008049070A3
WO2008049070A3 PCT/US2007/081812 US2007081812W WO2008049070A3 WO 2008049070 A3 WO2008049070 A3 WO 2008049070A3 US 2007081812 W US2007081812 W US 2007081812W WO 2008049070 A3 WO2008049070 A3 WO 2008049070A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antagonists
methods
antagonizing
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/081812
Other languages
French (fr)
Other versions
WO2008049070A9 (en
WO2008049070A2 (en
Inventor
Mark W Appleby
Mark W Rixon
Kenneth B Lewis
Zeren Gao
Rolf E Kuestner
Carl W Birks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to EP07863429A priority Critical patent/EP2064237A2/en
Priority to CA002666842A priority patent/CA2666842A1/en
Publication of WO2008049070A2 publication Critical patent/WO2008049070A2/en
Publication of WO2008049070A9 publication Critical patent/WO2008049070A9/en
Publication of WO2008049070A3 publication Critical patent/WO2008049070A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates IL-17RE antagonists, such as soluble receptors and anti-IL-17RE antibodies, which are useful in blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17C. IL-17C is a cytokine that is involved in inflammatory processes and human disease. IL-17RE is a receptor for IL-17C. The present invention includes soluble IL-17RE, soluable fusion peptide comprising one or more IL-17RE domains anti-IL-17RE antibodies and binding partners, as well as methods for antagonizing IL-17C using such soluble receptors, antibodies and binding partners.
PCT/US2007/081812 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same Ceased WO2008049070A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07863429A EP2064237A2 (en) 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same
CA002666842A CA2666842A1 (en) 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US82997206P 2006-10-18 2006-10-18
US60/829,972 2006-10-18
US86463306P 2006-11-07 2006-11-07
US60/864,633 2006-11-07
US86789306P 2006-11-30 2006-11-30
US60/867,893 2006-11-30
US89077607P 2007-02-20 2007-02-20
US60/890,776 2007-02-20
US91740407P 2007-05-11 2007-05-11
US60/917,404 2007-05-11

Publications (3)

Publication Number Publication Date
WO2008049070A2 WO2008049070A2 (en) 2008-04-24
WO2008049070A9 WO2008049070A9 (en) 2008-07-10
WO2008049070A3 true WO2008049070A3 (en) 2008-09-18

Family

ID=39226684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081812 Ceased WO2008049070A2 (en) 2006-10-18 2007-10-18 Il-17c antagonists and methods of using the same

Country Status (3)

Country Link
EP (1) EP2064237A2 (en)
CA (1) CA2666842A1 (en)
WO (1) WO2008049070A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
DK2769729T3 (en) 2007-09-04 2019-04-23 Compugen Ltd POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
NO2523688T3 (en) 2010-01-15 2018-03-10
AR083546A1 (en) * 2010-10-25 2013-03-06 Genentech Inc TREATMENT OF GASTROINTESTINAL INFLAMMATION, SORIASIS AND ASTHMA
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
SG11201401202YA (en) * 2011-10-19 2014-06-27 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders
MX2014009289A (en) 2012-02-01 2015-09-08 Compugen Ltd ANTIBODIES C1ORF32 AND USES OF THE SAME FOR THE TREATMENT OF CANCER.
EP3417878A1 (en) * 2012-06-12 2018-12-26 Orega Biotech Antagonists of il-17 isoforms and their uses
JP2015521591A (en) 2012-06-12 2015-07-30 オレガ・バイオテック IL-17 antagonists and uses thereof
EP3359161A1 (en) * 2015-10-05 2018-08-15 MorphoSys AG Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
ES2877376T3 (en) 2016-02-19 2021-11-16 Morphosys Ag Antibodies to IL-17C

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044840A2 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044840A2 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI TIE-SHI ET AL: "Identification and functional characterization of a novel interleukin 17 receptor: A possible mitogenic activation through ras/mitogen-activated protein kinase signaling pathway", CELLULAR SIGNALLING, vol. 18, no. 8, August 2006 (2006-08-01), pages 1287 - 1298, XP002476196, ISSN: 0898-6568 *

Also Published As

Publication number Publication date
CA2666842A1 (en) 2008-04-24
WO2008049070A9 (en) 2008-07-10
WO2008049070A2 (en) 2008-04-24
EP2064237A2 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
WO2005123778A3 (en) Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
ZA200704125B (en) Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
MXPA05010136A (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation.
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2007038703A3 (en) Il-17a and il-17f antagonists and methods of using the same
WO2004078114A3 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
WO2005080429A3 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2006028956A3 (en) Anti-fc-gamma riib receptor antibody and uses therefor
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2002089736A3 (en) Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
NO20072514L (en) Soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners and methods of use in inflammation
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2007114861A3 (en) Il-21 receptor antagonists
WO2005000207A3 (en) Pcdgf receptor antibodies and methods of use thereof
WO2006028810A3 (en) Method of wound healing using a2b adenosine receptor antagonists
WO2007059300A3 (en) Anti-alk antagonist and agonist antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07863429

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007863429

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009533531

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2666842

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP